Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study). Issue 10 (7th May 2018)

• Record Type: Journal Article
• Authors: Lu, Bin; Zhang, Ling; Wang, Jiangbin; Wang, Bangmao; Zou, Xiaoping; Fei, Guijun; Chen, Dongfeng; Wang, Xuehong; Wu, Bin; Zou, Duowu
• Is Part Of: Journal of gastroenterology and hepatology. Volume 33:Issue 10(2018)
• Page Start: 1722
• Page End: 1727
• Publication Date: 2018-05-07
• Subjects: China -- gastroesophageal reflux -- proton pump inhibitors -- treatment outcome; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.14143
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Empirical proton pump inhibitor (PPI) treatment is recommended as a diagnostic indicator for gastroesophageal reflux disease (GERD) and as a therapy for symptomatic control, with responses generally seen within 4 weeks. However, there are no real‐world data assessing the effectiveness of short‐term empirical treatment with PPIs in patients with GERD in China. Methods: The ENLIGHT study was a multicenter, prospective, observational study conducted in China. The primary outcome was the overall response rate after 4 weeks' empirical treatment with PPIs. Adult patients aged between 18 and 65 years of age, with a gastroesophageal reflux disease questionnaire score of ≥ 8, prescribed empirical PPI treatment by their physicians and with no planned endoscopy were eligible to participate. Statistical analyses were primarily descriptive. Results: Overall, 987 patients were eligible to participate and were included in the full analysis set (FAS); 707 patients were included in the per protocol set. In the FAS, esomeprazole was received by 57.1% of patients and was the most commonly used PPI. After 4‐week treatment, 71.1% (95% confidence interval [CI], 67.9% to 74.2%) of patients were considered responders to PPI. The response rate at the end of 2‐week PPI treatment reached 57.0% (95% CI, 52.5% to 61.7%). The median time to response was 13 days (95% CI, 12 to 15). Response rates at 2 and 4 weeks of the per protocol set were similar to those of the FAS. Conclusions: Short‐term empirical PPI treatment can provide an effective relief of GERD symptoms in most Chinese patients in real‐world practice.